INT MEDICAL (01501) Plans to Invest Approximately HK$283 Million to Subscribe for About 91.09 Million BRONCUS-B Shares

Stock News10-10

INT MEDICAL (01501) announced that on October 10, 2025 (after trading hours), the company entered into a subscription agreement with BRONCUS-B. Under the agreement, BRONCUS-B conditionally agreed to issue a total of 91,093,613 subscription shares to the company at a subscription price of HK$3.11 per subscription share, with a total consideration of HK$283,301,136.43 (excluding transaction costs), subject to the terms and conditions set out in the subscription agreement.

Upon completion, the company will hold a total of 91,093,613 BRONCUS-B shares, representing approximately 17.24% of BRONCUS-B's issued shares as of the announcement date (or approximately 17.30% excluding treasury shares) and approximately 14.38% of BRONCUS-B's enlarged issued shares following the issuance of subscription shares (or approximately 14.42% excluding treasury shares). BRONCUS-B's financial results will not be consolidated into the group's accounts.

The announcement stated that considering BRONCUS-B's rich product portfolio in the non-vascular intervention field, the subscription can further expand the company's strategic layout in the non-vascular intervention sector.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1125723119?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-10 19:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1125723119","market":"hk","top_or_hot":-1,"title":"INT MEDICAL (01501) Plans to Invest Approximately HK$283 Million to Subscribe for About 91.09 Million BRONCUS-B Shares","media":"Stock News","content":"<p>INT MEDICAL (01501) announced that on October 10, 2025 (after trading hours), the company entered into a subscription agreement with BRONCUS-B. Under the agreement, BRONCUS-B conditionally agreed to issue a total of 91,093,613 subscription shares to the company at a subscription price of HK$3.11 per subscription share, with a total consideration of HK$283,301,136.43 (excluding transaction costs), subject to the terms and conditions set out in the subscription agreement.</p>\n<p>Upon completion, the company will hold a total of 91,093,613 BRONCUS-B shares, representing approximately 17.24% of BRONCUS-B's issued shares as of the announcement date (or approximately 17.30% excluding treasury shares) and approximately 14.38% of BRONCUS-B's enlarged issued shares following the issuance of subscription shares (or approximately 14.42% excluding treasury shares). BRONCUS-B's financial results will not be consolidated into the group's accounts.</p>\n<p>The announcement stated that considering BRONCUS-B's rich product portfolio in the non-vascular intervention field, the subscription can further expand the company's strategic layout in the non-vascular intervention sector.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>INT MEDICAL (01501) Plans to Invest Approximately HK$283 Million to Subscribe for About 91.09 Million BRONCUS-B Shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nINT MEDICAL (01501) Plans to Invest Approximately HK$283 Million to Subscribe for About 91.09 Million BRONCUS-B Shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-10-10 19:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>INT MEDICAL (01501) announced that on October 10, 2025 (after trading hours), the company entered into a subscription agreement with BRONCUS-B. Under the agreement, BRONCUS-B conditionally agreed to issue a total of 91,093,613 subscription shares to the company at a subscription price of HK$3.11 per subscription share, with a total consideration of HK$283,301,136.43 (excluding transaction costs), subject to the terms and conditions set out in the subscription agreement.</p>\n<p>Upon completion, the company will hold a total of 91,093,613 BRONCUS-B shares, representing approximately 17.24% of BRONCUS-B's issued shares as of the announcement date (or approximately 17.30% excluding treasury shares) and approximately 14.38% of BRONCUS-B's enlarged issued shares following the issuance of subscription shares (or approximately 14.42% excluding treasury shares). BRONCUS-B's financial results will not be consolidated into the group's accounts.</p>\n<p>The announcement stated that considering BRONCUS-B's rich product portfolio in the non-vascular intervention field, the subscription can further expand the company's strategic layout in the non-vascular intervention sector.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01501","symbol_name":"瑛泰医疗","start_time":0,"source_url":"","article_id":"1125723119","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1125723119","pubTimestamp":1760094381,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"INT MEDICAL (01501) announced that on October 10, 2025 (after trading hours), the company entered into a subscription agreement with BRONCUS-B. Under the agreement, BRONCUS-B conditionally agreed to...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01501":"瑛泰医疗","BK1100":"医疗保健设备","BK1222":"医疗保健用品","02216":"堃博医疗-B"},"translate_title":"英特医疗(01501)拟出资约2.83亿港元认购约9109万股BRONCUS-B股","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02216":1,"01501":1},"content_text":"INT MEDICAL (01501) announced that on October 10, 2025 (after trading hours), the company entered into a subscription agreement with BRONCUS-B. Under the agreement, BRONCUS-B conditionally agreed to issue a total of 91,093,613 subscription shares to the company at a subscription price of HK$3.11 per subscription share, with a total consideration of HK$283,301,136.43 (excluding transaction costs), subject to the terms and conditions set out in the subscription agreement.\nUpon completion, the company will hold a total of 91,093,613 BRONCUS-B shares, representing approximately 17.24% of BRONCUS-B's issued shares as of the announcement date (or approximately 17.30% excluding treasury shares) and approximately 14.38% of BRONCUS-B's enlarged issued shares following the issuance of subscription shares (or approximately 14.42% excluding treasury shares). BRONCUS-B's financial results will not be consolidated into the group's accounts.\nThe announcement stated that considering BRONCUS-B's rich product portfolio in the non-vascular intervention field, the subscription can further expand the company's strategic layout in the non-vascular intervention sector.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1125723119","isCrawlerRequest":true}